

# Marco Metra

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/809523/marco-metra-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

696  
papers

41,777  
citations

95  
h-index

189  
g-index

824  
ext. papers

53,959  
ext. citations

7.9  
avg, IF

7.09  
L-index

#	Paper	IF	Citations
696	Sarcopenia detected by computed tomography: a simple tool for screening transcatheter aortic valve implantation candidates. <i>Journal of Cardiovascular Medicine</i> , <b>2022</b> , 23, 69-70	1.9	0
695	Sex-related differences in patients with coronavirus disease 2019: results of the Cardio-COVID-Italy multicentre study.. <i>Journal of Cardiovascular Medicine</i> , <b>2022</b> , 23, 254-263	1.9	0
694	Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the Cardio-COVID-Italy Multicenter Study).. <i>American Journal of Cardiology</i> , <b>2022</b> ,	3	3
693	European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society of Cardiology.. <i>European Journal of Heart Failure</i> , <b>2022</b> , 24, 132-142	12.3	4
692	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology.. <i>European Journal of Heart Failure</i> , <b>2022</b> , 24, 143-168	12.3	7
691	January 2022 at a glance: time for the new ESC guidelines on heart failure.. <i>European Journal of Heart Failure</i> , <b>2022</b> , 24, 1-3	12.3	
690	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC.. <i>European Journal of Heart Failure</i> , <b>2022</b> , 24, 4-131	12.3	50
689	Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction.. <i>Drugs</i> , <b>2022</b> , 82, 375	12.1	2
688	Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure.. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2022</b> , 17, 228-239	6.9	0
687	Pathophysiological pathways related to high plasma GDF-15 concentrations in patients with heart failure.. <i>European Journal of Heart Failure</i> , <b>2022</b> ,	12.3	1
686	Blood Pressure Drops During Hospitalization for Acute Heart Failure Treated With Serelaxin: A Patient-Level Analysis of 4 Randomized Controlled Trials.. <i>Circulation: Heart Failure</i> , <b>2022</b> , CIRCHEARTFAILURE12100919	7.6	0
685	Endothelial dysfunction in COVID-19 patients assessed with Endo-PAT2000.. <i>Monaldi Archives for Chest Disease</i> , <b>2022</b> ,	2.7	2
684	March 2022 at a glance: focus on medical therapy, prevention and comorbidities.. <i>European Journal of Heart Failure</i> , <b>2022</b> , 24, 403-405	12.3	0
683	Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure.. <i>Clinical Research in Cardiology</i> , <b>2022</b> , 1	6.1	0
682	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF.. <i>Circulation: Heart Failure</i> , <b>2022</b> , CIRCHEARTFAILURE121008970	7.6	0
681	Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis.. <i>Circulation</i> , <b>2022</b> , 145, 1123-1139	16.7	13
680	Differences in biomarkers and molecular pathways according to age for patients with HFrEF. <i>Cardiovascular Research</i> , <b>2021</b> , 117, 2228-2236	9.9	3

679	Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 110, 1020-1028	6.1	10
678	November 2021 at a glance: focus on prevention, comorbidities, cardiogenic shock and novel devices. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1803-1805	12.3	
677	Sodium-glucose co-transporter 2 inhibitors as an early, first line therapy in patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	9
676	Outcomes Stratified by Adapted Inclusion Criteria After Mitral Edge-to-Edge Repair. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 2408-2421	15.1	2
675	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis. <i>Cardiovascular Research</i> , <b>2021</b> ,	9.9	3
674	Roadmap for the management of heart failure patients during the vulnerable phase after heart failure hospitalizations: how to implement excellence in clinical practice.. <i>Journal of Cardiovascular Medicine</i> , <b>2021</b> , 23,	1.9	4
673	'Time is prognosis' in heart failure: time-to-treatment initiation as a modifiable risk factor. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 4444	3.7	4
672	Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 24, 230	12.3	4
671	Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical treatment in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	6
670	Worsening renal function in acute heart failure in the context of diuretic response. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	1
669	Creatine deficiency and heart failure. <i>Heart Failure Reviews</i> , <b>2021</b> , 1	5	1
668	COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1806-1818	12.3	7
667	Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 890-903	7.9	0
666	Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2021</b> ,	16.2	9
665	Antithrombotic and anticoagulation therapies in cardiogenic shock: a critical review of the published literature. <i>ESC Heart Failure</i> , <b>2021</b> ,	3.7	2
664	October 2021 at a glance: focus on imaging, biomarkers and comorbidities. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1569-1571	12.3	
663	Intra-Aortic Balloon Pumping in Acute Decompensated Heart Failure With Hypoperfusion: From Pathophysiology to Clinical Practice. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008527	7.6	6
662	Unusual intracardiac thrombosis in two patients with coronavirus disease 2019 (COVID-19): case series. <i>European Heart Journal - Case Reports</i> , <b>2021</b> , 5, ytaa518	0.9	2

661	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	17
660	Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2021</b> ,	0.7	1
659	Prognostic Value of Pre-operative Atrial Fibrillation in Patients With Secondary Mitral Regurgitation Undergoing MitraClip Implantation. <i>American Journal of Cardiology</i> , <b>2021</b> , 143, 51-59	3	2
658	Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 947-953	12.3	4
657	Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta-blockers in patients hospitalized for acute heart failure. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 1944-1953	3.7	5
656	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Preventive Cardiology (EAPC) for the ESC. <i>European Heart Journal</i> , <b>2021</b>	9.5	29
655	March 2021 at a glance: focus on epidemiology, prevention and COVID-19. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 347-349	12.3	0
654	The value of spot urinary creatinine as a marker of muscle wasting in patients with new-onset or worsening heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , <b>2021</b> , 12, 555-567	10.3	3
653	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and	12.3	143
652	Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 983-991	12.3	16
651	Evidence-Based Management of Acute Heart Failure. <i>Canadian Journal of Cardiology</i> , <b>2021</b> , 37, 621-631	3.8	5
650	Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 567-577	12.3	3
649	Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e007871	7.6	4
648	Myocardial Involvement in COVID-19: an Interaction Between Comorbidities and Heart Failure with Preserved Ejection Fraction. A Further Indication of the Role of Inflammation. <i>Current Heart Failure Reports</i> , <b>2021</b> , 18, 99-106	2.8	9
647	Temporal Relation Between Second Dose BNT162b2 mRNA Covid-19 Vaccine and Cardiac involvement in a Patient with Previous SARS-COV-2 Infection. <i>IJC Heart and Vasculature</i> , <b>2021</b> , 100778	2.4	9
646	Thromboembolism in Heart Failure Patients in Sinus Rhythm: Epidemiology, Pathophysiology, Clinical Trials, and Future Direction. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 243-253	7.9	4
645	April 2021 at a glance: focus on systolic function, quality of life and treatment in heart failure. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 505-506	12.3	
644	Co-infection of chlamydia pneumoniae and mycoplasma pneumoniae with SARS-CoV-2 is associated with more severe features. <i>Journal of Infection</i> , <b>2021</b> , 82, e4-e7	18.9	10

643	Impaired High-Density Lipoprotein Function in Patients With Heart Failure. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e019123	6	2
642	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 872-881	12.3	41
641	Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> , 7, 539-546	6.4	7
640	May 2021 at a glance: focus on acute heart failure and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 691-692	12.3	
639	Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to Tailored Treatment in chronic heart failure. <i>Clinical Cardiology</i> , <b>2021</b> , 44, 780-788	3.3	1
638	Heart failure and pulmonary hypertension in a patient with partial anomalous pulmonary venous return and hyperthyroidism: a case report. <i>Journal of Cardiovascular Medicine</i> , <b>2021</b> , 22, e15-e17	1.9	
637	Non-adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography-tandem mass spectrometry (results of a prospective multicentre study). <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1182-1190	12.3	5
636	Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 3168-3179	3.7	5
635	Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1170-1181	12.3	5
634	Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?. <i>Heart Failure Reviews</i> , <b>2021</b> , 1	5	2
633	Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection. <i>IJC Heart and Vasculature</i> , <b>2021</b> , 34, 1007744	2.4	32
632	June 2021 at a glance: focus on epidemiology, biomarkers and medical treatment. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 847-849	12.3	
631	Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. <i>Journal of Cardiac Failure</i> , <b>2021</b> , 27, 670-676	3.3	3
630	July 2021 at a glance: focus on blood volume distribution, haemodynamics and adherence to therapy. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1059-1061	12.3	
629	Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study. <i>Europace</i> , <b>2021</b> , 23, 1603-1611	3.9	4
628	Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 97-108	15.1	25
627	The prognostic value of serial troponin measurements in patients admitted for COVID-19. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 3504-3511	3.7	8
626	Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19: Insights from the Cardio-COVID-Italy multicenter study. <i>International Journal of Infectious Diseases</i> , <b>2021</b> , 108, 270-273	10.5	5

625	SARS-CoV-2, myocardial injury and inflammation: insights from a large clinical and autopsy study. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 110, 1822-1831	6.1	2
624	Treatment of secondary mitral regurgitation in patients with heart failure: when left ventricular ejection fraction may become not crucial. <i>EuroIntervention</i> , <b>2021</b> , 17, e271-e273	3.1	
623	The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , <b>2021</b> , 27, 808-811	3.3	0
622	Heart failure treatment up-titration and outcome and age: an analysis of BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 436-444	12.3	6
621	Drug development in oncology and devices-lessons for heart failure drug development and approval? a review. <i>Heart Failure Reviews</i> , <b>2021</b> , 26, 255-262	5	
620	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 117-128	59.2	408
619	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 105-116	59.2	164
618	Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 146-157	7.9	5
617	Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 43-57	12.3	5
616	Discontinuation and non-publication of heart failure randomized controlled trials: a call to publish all trial results. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 16-25	3.7	1
615	Renal failure after trans-catheter aortic valve implantation. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 83, 86-87	3.9	0
614	Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAX-AHF-2 study. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 58-67	12.3	5
613	Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	9
612	Thrombotic risk in patients with COVID-19. <i>Reviews in Cardiovascular Medicine</i> , <b>2021</b> , 22, 277-286	3.9	2
611	January 2021 at a glance: focus on sex differences, acute heart failure and exercise capacity. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1-2	12.3	
610	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	28
609	February 2021 at a glance: focus on amyloidosis, myocarditis and cardiomyopathy. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 201-202	12.3	
608	August 2021 at a glance: focus on cardiomyopathies, medical treatment and devices. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1247-1249	12.3	

607	Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1597-1609	12.3	6
606	Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 3547-3556	3.7	11
605	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 1065-1072	8	6
604	Impact of mitral regurgitation in patients with worsening heart failure: insights from BIostat-CHF. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1750-1758	12.3	8
603	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , <b>2021</b> , 42, 3599-3726	9.5	875
602	COVID-19 and Heart Failure: From Epidemiology During the Pandemic to Myocardial Injury, Myocarditis, and Heart Failure Sequelae. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 713560	5.4	12
601	Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist device-supported patients for the non-left ventricular assist device specialist healthcare provider: Part 2: at the emergency department. <i>ESC Heart Failure</i> , <b>2021</b> ,	3.7	2
600	A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization-the first insight from the AC-TIVE Study. <i>European Journal of Preventive Cardiology</i> , <b>2021</b> ,	3.9	6
599	High troponin levels in patients hospitalized for coronavirus disease 2019: a maker or a marker of prognosis?. <i>Journal of Cardiovascular Medicine</i> , <b>2021</b> , 22, 828-831	1.9	0
598	HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community. <i>ESC Heart Failure</i> , <b>2021</b> ,	3.7	2
597	Amended STRONG-HF study design. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1981-1982	12.3	0
596	September 2021 at a glance: focus on biomarkers, sex differences and adherence to medical treatment. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1419-1421	12.3	
595	HFA of the ESC position paper on the management of LVAD-supported patients for the non-LVAD specialist healthcare provider Part 3: at the hospital and discharge. <i>ESC Heart Failure</i> , <b>2021</b> ,	3.7	3
594	Systolic Blood Pressure and Outcome in Patients Admitted With Acute Heart Failure: An Analysis of Individual Patient Data From 4 Randomized Clinical Trials. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e022288	6	1
593	Congestion in Patients with Advanced Heart Failure: Assessment and Treatment. <i>Heart Failure Clinics</i> , <b>2021</b> , 17, 575-586	3.3	3
592	The impact of COVID-19 pandemic on AMI and stroke mortality in Lombardy: Evidence from the epicenter of the pandemic. <i>PLoS ONE</i> , <b>2021</b> , 16, e0257910	3.7	1
591	Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials. <i>American Heart Journal</i> , <b>2021</b> , 240, 73-80	4.9	0
590	Percutaneous Edge-to-Edge Mitral Valve Repair: Beyond the Left Heart. <i>Journal of the American Society of Echocardiography</i> , <b>2021</b> , 34, 1038-1045	5.8	0

589	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	18
588	Maternal hemodynamics, arterial stiffness and elastic aortic properties in twin pregnancy. <i>Physiological Measurement</i> , <b>2021</b> , 41, 125001	2.9	0
587	COAPT-Like Profile Predicts Long-Term Outcomes in Patients With Secondary Mitral Regurgitation Undergoing MitraClip Implantation. <i>JACC: Cardiovascular Interventions</i> , <b>2021</b> , 14, 15-25	5	19
586	Impact of RAAS Inhibitors on Clinical Outcome and Mortality in Patients With STEMI During the COVID-19 Era: A Multicenter Observational Study.. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 792804	5.4	0
585	December 2021 at a glance: focus on medical treatment, valvular heart disease and prognostic models.. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1993-1994	12.3	
584	A year in heart failure: an update of recent findings.. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 4370-4393	3.7	4
583	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. <i>Cardiovascular Research</i> , <b>2021</b> ,	9.9	3
582	The 'Ten Commandments' of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	8
581	Challenges and Future Perspectives of Transcatheter Tricuspid Valve Interventions: Adopt Old Strategies or Adapt to New Opportunities?. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	4
580	Management of acute coronary syndromes during the COVID-19 outbreak in Lombardy: The "macro-hub" experience. <i>IJC Heart and Vasculature</i> , <b>2020</b> , 31, 100662	2.4	7
579	October 2020 at a glance: focus on outcomes, valve disease and patients' monitoring. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1745-1746	12.3	
578	Guideline-directed medical therapy for heart failure does not exist: a non-judgmental framework for describing the level of adherence to evidence-based drug treatments for patients with a reduced ejection fraction. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1759-1767	12.3	21
577	Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. <i>European Heart Journal</i> , <b>2020</b> , 41, 1810-1817	9.5	277
576	Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. <i>European Heart Journal</i> , <b>2020</b> , 41, 1821-1829	9.5	299
575	The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2020</b> , 6, 394-404	6.4	7
574	COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 957-966	12.3	137
573	Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. <i>Autoimmunity Reviews</i> , <b>2020</b> , 19, 102568	13.6	509
572	May 2020 at a glance: ischaemic heart failure and sex-related differences. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 761-762	12.3	1



571	Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 941-956	12.3	60
570	Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1315-1341	12.3	83
569	Publication Rates of Heart Failure Clinical Trials Remain Low. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 3151-3161	15.1	3
568	Direct oral anticoagulants across the heart failure spectrum: the precision medicine era. <i>Heart Failure Reviews</i> , <b>2020</b> , 1	5	1
567	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , <b>2020</b> , 41, 2109-2117	9.5	42
566	Clinical Role of CA125 in Worsening Heart Failure: A BIOSTAT-CHF Study Subanalysis. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 386-397	7.9	17
565	The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1022-1031	12.3	11
564	Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). <i>JAMA Cardiology</i> , <b>2020</b> , 5, 819-824	16.2	1121
563	The brain-heart connection: a multiple sclerosis relapse presenting as Takotsubo Syndrome. A case report and literature review. <i>Monaldi Archives for Chest Disease</i> , <b>2020</b> , 90,	2.7	5
562	Heart failure with mid-range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 381-399	3.7	17
561	March 2020 at a glance: heart failure with preserved ejection fraction, left atrial myopathy, atrial fibrillation and cardiac amyloidosis. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 389-390	12.3	1
560	Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-AHF-2 trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 726-738	12.3	12
559	In-hospital and long-term mortality for acute heart failure: analysis at the time of admission to the emergency department. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 2650-2661	3.7	8
558	Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1495-1503	12.3	56
557	Distinct Pathological Pathways in Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 234-242	7.9	12
556	Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1684-1693	12.3	19
555	Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 967-977	6.1	3
554	Percutaneous treatment of mitral regurgitation: looking for a final model. <i>Internal and Emergency Medicine</i> , <b>2020</b> , 15, 13-15	3.7	

553	January 2020 at a glance: translational medicine, predictors of outcome and treatments. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1-2	12.3	3
552	Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 329-340	7.9	61
551	Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1298-1314	12.3	23
550	Centralization of the ST elevation myocardial infarction care network in the Lombardy region during the COVID-19 outbreak. <i>International Journal of Cardiology</i> , <b>2020</b> , 312, 24-26	3.2	11
549	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1424-1437	12.3	13
548	A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 821-833	12.3	11
547	Acute heart failure: More questions than answers. <i>Progress in Cardiovascular Diseases</i> , <b>2020</b> , 63, 599-606	8.5	16
546	Cardiogenic Shock due to COVID-19-Related Myocarditis in a 19-Year-Old Autistic Patient. <i>Journal of Medical Cases</i> , <b>2020</b> , 11, 207-210	0.2	1
545	Diagnostic and prognostic value of low QRS voltages in cardiomyopathies: old but gold. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> ,	3.9	3
544	Right ventricular deformation and right ventricular-arterial coupling in patients with heart failure due to severe aortic stenosis undergoing TAVI: long-term results. <i>American Journal of Cardiovascular Disease</i> , <b>2020</b> , 10, 150-163	0.9	3
543	Impact of disproportionate secondary mitral regurgitation in patients undergoing edge-to-edge percutaneous mitral valve repair. <i>EuroIntervention</i> , <b>2020</b> , 16, 413-420	3.1	13
542	Patient with heart failure: importance to treat valvular diseases. <i>European Heart Journal Supplements</i> , <b>2020</b> , 22, P38-P41	1.5	1
541	December 2020 at a glance: focus on COVID-19, comorbidities and palliative care. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2173-2174	12.3	2
540	Diuretic Resistance and Chronic Heart Failure <b>2020</b> , 121-135		1
539	Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 1048-1059	6.1	12
538	Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test. <i>Journal of Cardiac Failure</i> , <b>2020</b> , 26, 932-943	3.3	2
537	Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 70-80	12.3	14
536	Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1147-1155	12.3	22

535	Genetic risk and atrial fibrillation in patients with heart failure. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 519-527	12.3	3
534	Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 371-380	3.7	11
533	Evaluation of kidney function throughout the heart failure trajectory—a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 584-603	12.3	82
532	Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 315-329	12.3	16
531	Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 683-691	12.3	19
530	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 196-213	12.3	85
529	Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 181-195	12.3	27
528	Cardiovascular and non-cardiovascular death distinction: the utility of troponin beyond N-terminal pro-B-type natriuretic peptide. Findings from the BIostat-CHF study. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 81-89	12.3	10
527	The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2102-2111	12.3	9
526	Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 973-983	7.9	8
525	Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1984-1986	12.3	44
524	July 2020 at a glance: focus on imaging and cardiomyopathies. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1057-1059	12.3	
523	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2160-2171	12.3	24
522	Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 1795-1807	15.1	26
521	MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry. <i>Journal of Heart and Lung Transplantation</i> , <b>2020</b> , 39, 1353-1362	5.8	27
520	ACE2 down-regulation may contribute to the increased thrombotic risk in COVID-19. <i>European Heart Journal</i> , <b>2020</b> , 41, 3200	9.5	7
519	Sinus Node Dysfunction in a Young Patient With COVID-19. <i>JACC: Case Reports</i> , <b>2020</b> , 2, 1240-1244	1.2	16
518	Implications of serial measurements of natriuretic peptides in heart failure: insights from BIostat-CHF. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1486-1490	12.3	4

517	Coronavirus 2019 Disease (COVID-19), Systemic Inflammation, and Cardiovascular Disease. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e017756	6	21
516	Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 999-1008	7.9	0
515	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. <i>Lancet, The</i> , <b>2020</b> , 396, 1895-1904	40	162
514	Heart failure in the last year: progress and perspective. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 3505	3.7	24
513	November 2020 at a glance: focus on comorbidities and medical treatment. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1937-1938	12.3	0
512	Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2238-2247	12.3	58
511	Atrial fibrillation in the COVID-19 era: simple bystander or marker of increased risk?. <i>European Heart Journal</i> , <b>2020</b> , 41, 3094	9.5	15
510	June 2020 at a glance: focus on COVID-19, quality of life and comorbidities. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 917-918	12.3	4
509	Impact of COVID-2019 outbreak on prevalence, clinical presentation and outcomes of ST-elevation myocardial infarction. <i>Journal of Cardiovascular Medicine</i> , <b>2020</b> , 21, 874-881	1.9	18
508	Coronavirus disease 2019 (COVID-19) in the heart transplant population: a single-centre experience. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2020</b> , 58, 899-906	3	12
507	Elevated plasma endothelin-1 is related to low natriuresis, clinical signs of congestion, and poor outcome in acute heart failure. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 3536	3.7	8
506	September 2020 at a glance: focus on heart failure with preserved ejection fraction and medical therapy. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1493-1494	12.3	
505	Second European Society of Cardiology Cardiac Resynchronization Therapy Survey: the Italian cohort. <i>Journal of Cardiovascular Medicine</i> , <b>2020</b> , 21, 634-640	1.9	0
504	August 2020 at a glance: focus on neurohormonal antagonists and electrolytes. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1289-1290	12.3	
503	Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019: Results of a Multicenter Study. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 1274-1280	16.2	95
502	Coronavirus disease 2019 and cardiovascular implications. <i>Journal of Cardiovascular Medicine</i> , <b>2020</b> , 21, 725-732	1.9	13
501	Implications for the Care of Patients With COVID-19 and Inflammatory Myocardial Disease-Reply. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 1306-1307	16.2	1
500	Acute Heart Failure <b>2020</b> , 501-519		

499	The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 331-338	6.1	17
498	Mega-trials in heart failure: effects of dilution in examination of new therapies. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1698-1707	12.3	6
497	September 2019 at a glance: focus on devices. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1049-1050	12.3	
496	October 2019 at a glance: epidemiology, prevention, and modes of death. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1167-1168	12.3	
495	Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. <i>Lancet, The</i> , <b>2019</b> , 394, 1254-1263	40	83
494	Treatment of functional mitral regurgitation in chronic heart failure: can we get a 'proof of concept' from the MITRA-FR and COAPT trials?. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 852-861	12.3	53
493	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1169-1186	12.3	325
492	Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 844-851	12.3	47
491	June 2019 at a glance: from genetics to haemodynamics, biomarkers and imaging for the prediction of outcomes. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 697-698	12.3	
490	Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 715-731	12.3	193
489	Elastic aortic properties in cystic fibrosis adults without cardiovascular risk factors: A case-control study. <i>Echocardiography</i> , <b>2019</b> , 36, 1118-1122	1.5	7
488	May 2019 at a glance: epidemiology, drug effects on biomarkers, adverse events with LVAD. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 541-542	12.3	
487	Focus on echocardiographic right ventricular strain analysis in cystic fibrosis adults without cardiovascular risk factors: a case-control study. <i>Internal and Emergency Medicine</i> , <b>2019</b> , 14, 1279-1285	3.7	5
486	The clinical significance of interleukin-6 in heart failure: results from the BIostat-CHF study. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 965-973	12.3	81
485	Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure. <i>Circulation: Heart Failure</i> , <b>2019</b> , 12, e005544	7.6	13
484	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 553-576	12.3	118
483	Clinical profiles in acute heart failure: an urgent need for a new approach. <i>ESC Heart Failure</i> , <b>2019</b> , 6, 464-474	3.7	26
482	March 2019 at a glance: epidemiology and clinical trials. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 259-269	12.3	

481	Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 732-743	12.3	37
480	The role of ventricular-arterial coupling in cardiac disease and heart failure: assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases, European Association of Cardiovascular Imaging, and Heart Failure Association. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 402-424	12.3	95
479	Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction. <i>Heart</i> , <b>2019</b> , 105, 1182-1189	5.1	49
478	April 2019 at a glance: prediction of heart failure, left atrial function, cardio-oncology. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 393-394	12.3	
477	Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , <b>2019</b> , 25, 703-711	3.3	6
476	Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 624-633	12.3	39
475	Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1459-1467	12.3	13
474	August 2019 at a glance: arrhythmogenic cardiomyopathy, biomarkers of inflammation, insulin treatment, initiation of sacubitril/valsartan, and pharmacy-based intervention to increase medication adherence. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 951-952	12.3	
473	Sacubitril/Valsartan: Updates and Clinical Evidence for a Disease-Modifying Approach. <i>Drugs</i> , <b>2019</b> , 79, 1543-1556	12.1	7
472	Cardiac implantable electronic devices with a defibrillator component and all-cause mortality in left ventricular assist device carriers: results from the PCHF-VAD registry. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1129-1141	12.3	10
471	Effects of Serelaxin in Patients with Acute Heart Failure. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 716-726	59.2	92
470	Trajectories of Changes in Renal Function in Patients with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , <b>2019</b> , 25, 866-874	3.3	7
469	July 2019 at a glance: imaging of congestion, sodium-glucose co-transporter 2 inhibitors, myocardial function and MitraClip trials. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 821-822	12.3	1
468	Geographical location affects the levels and association of trimethylamine N-oxide with heart failure mortality in BIostat-CHF: a post-hoc analysis. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1291-1294	12.3	11
467	The New Heart Failure Association Definition of Advanced Heart Failure. <i>Cardiac Failure Review</i> , <b>2019</b> , 5, 5-8	4.2	13
466	Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial. <i>ESC Heart Failure</i> , <b>2019</b> , 6, 1188-1198	3.7	13
465	Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1561-1570	12.3	4
464	Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 970-979	7.9	13

463	February 2019 at a glance: pathophysiology, exercise capacity, diuretics and valve disease. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 135-136	12.3	
462	Highlights in heart failure. <i>ESC Heart Failure</i> , <b>2019</b> , 6, 1105-1127	3.7	48
461	November 2019 at a glance. Chronic and acute heart failure: from epidemiology to treatment. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1297-1298	12.3	
460	December 2019 at a glance: economic burden, co-morbidities, and prognosis. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1485-1486	12.3	0
459	Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1651-1658	12.3	26
458	Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1586-1595	12.3	12
457	Elastic properties of ascending aorta and ventricular-arterial coupling in women with previous pregnancy complicated by HELLP syndrome. <i>Journal of Hypertension</i> , <b>2019</b> , 37, 356-364	1.9	8
456	New drugs for the treatment of chronic heart failure with a reduced ejection fraction: What the future may hold. <i>Journal of Cardiovascular Medicine</i> , <b>2019</b> , 20, 650-659	1.9	5
455	Inappropriate left ventricular mass after preeclampsia: another piece of the puzzle Inappropriate LVM and PE. <i>Hypertension Research</i> , <b>2019</b> , 42, 522-529	4.7	7
454	Adrenomedullin in heart failure: pathophysiology and therapeutic application. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 163-171	12.3	69
453	The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 137-155	12.3	270
452	Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 218-226	12.3	13
451	Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. <i>Clinical Research in Cardiology</i> , <b>2019</b> , 108, 797-805	6.1	7
450	Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 208-217	12.3	33
449	Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 877-886	12.3	34
448	Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 112-120	12.3	24
447	Treatments targeting inotropy. <i>European Heart Journal</i> , <b>2019</b> , 40, 3626-3644	9.5	51
446	Left ventricular reverse remodelling predicts long-term outcomes in patients with functional mitral regurgitation undergoing MitraClip therapy: results from a multicentre registry. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 196-204	12.3	23

445	Effects of ivabradine on endothelial function, aortic properties and ventricular-arterial coupling in chronic systolic heart failure patients. <i>Cardiovascular Therapeutics</i> , <b>2018</b> , 36, e12323	3.3	10
444	Redefining biomarkers in heart failure. <i>Heart Failure Reviews</i> , <b>2018</b> , 23, 237-253	5	17
443	February 2018 at a glance: heart and brain interaction, prognostic variables, and acute heart failure and post-discharge outcomes. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 191-192	12.3	
442	Acute heart failure: lessons learned, roads ahead. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 842-850	12.3	13
441	Mineralocorticoid receptor antagonists for heart failure: a real-life observational study. <i>ESC Heart Failure</i> , <b>2018</b> , 5, 267-274	3.7	4
440	April 2018 at a glance: focus on prognostic variables. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 625-626	12.3	
439	March 2018 at a glance: clinical trials, co-morbidities and treatment of mitral regurgitation. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 411-412	12.3	
438	Evaluation of an individualized dose titration regimen of patiomer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. <i>ESC Heart Failure</i> , <b>2018</b> , 5, 257-266	3.7	34
437	January 2018 at a glance: biomarkers, co-morbidities and mechanical circulatory support. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1-2	12.3	
436	Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 386-398	15.1	22
435	Proportional pulse pressure relates to cardiac index in stabilized acute heart failure patients. <i>Clinical and Experimental Hypertension</i> , <b>2018</b> , 40, 637-643	2.2	2
434	Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 260-267	12.3	19
433	Heart rate as a prognostic marker and therapeutic target in acute and chronic heart failure. <i>International Journal of Cardiology</i> , <b>2018</b> , 253, 97-104	3.2	21
432	Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. <i>International Journal of Cardiology</i> , <b>2018</b> , 253, 91-96	3.2	2
431	Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 923-930	12.3	41
430	Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. <i>International Journal of Cardiology</i> , <b>2018</b> , 253, 84-90	3.2	32
429	Negotiating renal dysfunction when treating patients with heart failure. <i>Expert Review of Cardiovascular Therapy</i> , <b>2018</b> , 16, 113-122	2.5	3
428	Educational needs and application of guidelines in the management of patients with mitral regurgitation. A European mixed-methods study. <i>European Heart Journal</i> , <b>2018</b> , 39, 1295-1303	9.5	27



427	May 2018 at a glance: the central role of co-morbidities. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 833-834		
426	Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial. <i>JACC: Heart Failure</i> , <b>2018</b> , 6, 298-307	7.9	2
425	Mechanism of cardiovascular toxicity by proteasome inhibitors: New paradigm derived from clinical and pre-clinical evidence. <i>European Journal of Pharmacology</i> , <b>2018</b> , 828, 80-88	5.3	24
424	Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. <i>International Journal of Cardiology</i> , <b>2018</b> , 258, 185-191	3.2	78
423	What will be the impact of sacubitril/valsartan in clinical practice?. <i>Journal of Cardiovascular Medicine</i> , <b>2018</b> , 19 Suppl 1, e88-e90	1.9	2
422	Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality. <i>Circulation</i> , <b>2018</b> , 137, 1320-1330	16.7	76
421	Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. <i>Clinical Research in Cardiology</i> , <b>2018</b> , 107, 170-181	6.1	22
420	Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 700-710	12.3	51
419	Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 317-322	12.3	14
418	Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 3-15	12.3	83
417	Dose-dependent efficacy of $\beta$ -blocker in patients with chronic heart failure and atrial fibrillation. <i>International Journal of Cardiology</i> , <b>2018</b> , 273, 141-146	3.2	10
416	Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion: A Post Hoc Analysis of the PROTECT Data. <i>Circulation: Heart Failure</i> , <b>2018</b> , 11, e004644	7.6	38
415	August 2018 at a glance: patients' outcomes, obesity and medical therapy. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1167-1168	12.3	1
414	Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 1081-1090	15.1	108
413	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. <i>European Heart Journal</i> , <b>2018</b> , 39, 3867-3875	9.5	33
412	June 2018 at a glance: peripartum cardiomyopathy and pathophysiology, prognosis, and device therapy of heart failure. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 949-950	12.3	2
411	Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 304-314	12.3	30
410	Coronary angiography in worsening heart failure: determinants, findings and prognostic implications. <i>Heart</i> , <b>2018</b> , 104, 606-613	5.1	9

409	A new educational program in heart failure drug development: the Brescia international master program. <i>Journal of Cardiovascular Medicine</i> , <b>2018</b> , 19, 411-421	1.9	7
408	Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. <i>Clinical Proteomics</i> , <b>2018</b> , 15, 35	5	5
407	Iron deficiency in heart failure. <i>Journal of Cardiovascular Medicine</i> , <b>2018</b> , 19, 706-716	1.9	3
406	Echocardiographic evaluation of diastolic dysfunction in young and healthy patients with psoriasis: A case-control study. <i>Monaldi Archives for Chest Disease</i> , <b>2018</b> , 88, 934	2.7	9
405	November 2018 at a glance: from prediction of heart failure in asymptomatic subjects to advanced chronic heart failure. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1503-1504	12.3	1
404	December 2018 at a glance: new imaging methods, translational cardiology and non-medical treatment. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1613-1614	12.3	
403	Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , <b>2018</b> , 24, 512-519	3.3	7
402	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2018</b> , 11, e004783	5.8	7
401	October 2018 at a glance: from demographic variables to genotype-phenotype interactions. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1373-1374	12.3	
400	A Critical Appraisal of Short-Term End Points in Acute Heart Failure Clinical Trials. <i>Journal of Cardiac Failure</i> , <b>2018</b> , 24, 783-792	3.3	6
399	September 2018 at a glance: co-morbidities, heart failure with preserved ejection fraction and mineralocorticoid receptor antagonists. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1245-1246	12.3	2
398	Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. <i>International Journal of Cardiology</i> , <b>2018</b> , 271, 132-139	3.2	74
397	Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1505-1535	12.3	285
396	Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis: Multicenter Lombardy Registry. <i>Circulation</i> , <b>2018</b> , 138, 1088-1099	16.7	127
395	Prognostic evaluation of the elastic properties of the ascending aorta in dilated cardiomyopathy. <i>European Journal of Clinical Investigation</i> , <b>2018</b> , 48, e12950	4.6	4
394	July 2018 at a glance: practical guidance in acute heart failure, pathophysiology and clinical trials of medical therapy. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1079-1080	12.3	
393	Waist-to-hip ratio and mortality in heart failure. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1269-1277	12.3	56
392	Obstructive sleep apnoea-hypopnoea and arrhythmias: new updates. <i>Journal of Cardiovascular Medicine</i> , <b>2017</b> , 18, 490-500	1.9	26

391	Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	9
390	A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1001-1010	12.3	57
389	January 2017 at a glance: oncology, diabetes and antidiabetic treatment, pulmonary hypertension. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 7-8	12.3	2
388	Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. <i>Clinical Research in Cardiology</i> , <b>2017</b> , 106, 444-456	6.1	4
387	Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS). <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 739-747	12.3	21
386	Prognostic role of $\beta$ -blocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 904-914	12.3	19
385	Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. <i>Heart</i> , <b>2017</b> , 103, 407-413	5.1	42
384	Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 627-634	12.3	110
383	Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 728-738	12.3	24
382	March 2017 at a glance: pathophysiology, imaging, biomarkers and devices. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 299-300	12.3	
381	Percutaneous edge-to-edge mitral valve repair for the treatment of acute mitral regurgitation complicating myocardial infarction: A single centre experience. <i>International Journal of Cardiology</i> , <b>2017</b> , 234, 53-57	3.2	28
380	Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 800-809	12.3	91
379	Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1495-1503	12.3	111
378	Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). <i>European Heart Journal</i> , <b>2017</b> , 38, 2364-2373	9.5	72
377	Arrhythmias and cardiomyopathy: when arrhythmias come first. <i>Journal of Cardiovascular Medicine</i> , <b>2017</b> , 18 Suppl 1, e145-e148	1.9	2
376	Heart failure. <i>Lancet, The</i> , <b>2017</b> , 390, 1981-1995	40	306
375	Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2017</b> , 5, 507-517	7.9	49
374	Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 3029-3039	15.1	41

373	June 2017 at a glance: biomarkers and medical treatment. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 699-700	12.3	
372	Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial. <i>American Heart Journal</i> , <b>2017</b> , 190, 113-122	4.9	9
371	Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1520-1529	12.3	66
370	April 2017 at a glance: cardiomyopathies and clinical trials. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 447-448	12.3	
369	Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. <i>American Heart Journal</i> , <b>2017</b> , 187, 62-69	4.9	6
368	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 718-727	12.3	15
367	February 2017 at a glance: fibrosis, acute heart failure and neurologic abnormalities. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 165-166	12.3	0
366	Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	11
365	October 2017 at a glance: phenotyping heart failure, co-morbidities, use of evidence-based therapy and new treatments. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1216-1217	12.3	3
364	The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIostat-CHF Subanalysis. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 2128-2136	15.1	24
363	High-dose atorvastatin versus moderate dose on early vascular protection after ST-elevation myocardial infarction. <i>Drug Design, Development and Therapy</i> , <b>2017</b> , 11, 3425-3434	4.4	8
362	September 2017 at a glance: epidemiology, prognosis, Mediterranean diet and different viewpoints on aspirin. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1084-1085	12.3	0
361	Frequency and Prognostic Significance of Abnormal Liver Function Tests in Patients With Cardiogenic Shock. <i>American Journal of Cardiology</i> , <b>2017</b> , 120, 1090-1097	3	13
360	Prognostic value of the absolute lymphocyte count in patients admitted for acute heart failure. <i>Journal of Cardiovascular Medicine</i> , <b>2017</b> , 18, 859-865	1.9	9
359	August 2017 at a glance: tailored treatment, acute heart failure and cardiac resynchronization. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 969-970	12.3	1
358	November 2017 at a glance: quality of care and disease management. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1351-1352	12.3	1
357	A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1310-1320	12.3	39
356	Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. <i>Circulation</i> , <b>2017</b> , 136, 1374-1383	16.7	179

355	Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial : Differential Response in Acute Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , <b>2017</b> , 31, 281-293	3.9	6
354	Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study. <i>Clinical Research in Cardiology</i> , <b>2017</b> , 106, 280-292	6.1	12
353	Heart failure 2016: still more questions than answers. <i>International Journal of Cardiology</i> , <b>2017</b> , 227, 766-777	3.7	12
352	Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , <b>2017</b> , 23, 231-239	3.3	22
351	Heart failure and anemia: Effects on prognostic variables. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 37, 56-63	3.9	23
350	Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials). <i>American Journal of Cardiology</i> , <b>2017</b> , 119, 290-296	3	28
349	Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 241-249	12.3	15
348	ANMCO/SIC Consensus Document: cardiology networks for outpatient heart failure care. <i>European Heart Journal Supplements</i> , <b>2017</b> , 19, D89-D101	1.5	5
347	December 2017 at a glance: left ventricular ejection fraction, exercise capacity, peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1562-1563	12.3	1
346	Plasma Neutrophil Gelatinase-Associated Lipocalin and Predicting Clinically Relevant Worsening Renal Function in Acute Heart Failure. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	10
345	Cardiopoeitic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. <i>European Heart Journal</i> , <b>2017</b> , 38, 648-660	9.5	113
344	Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1284-1293	12.3	46
343	Mode of Death After Acute Heart Failure Hospitalization - A Clue to Possible Mechanisms. <i>Circulation Journal</i> , <b>2016</b> , 80, 17-23	2.9	12
342	Cardiorenal Interactions. <i>Heart Failure Clinics</i> , <b>2016</b> , 12, 335-47	3.3	9
341	In-hospital worsening heart failure in patients admitted for acute heart failure. <i>International Journal of Cardiology</i> , <b>2016</b> , 225, 353-361	3.2	11
340	November 2016 at a glance: the left atrium, screening for heart failure, multimodality imaging for cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1305-1306	12.3	
339	October 2016 at a glance: treatment of heart failure. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1209-1210	12.3	
338	A systems BIOlogy Study to Tailored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 716-26	12.3	94

337	Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1041-50	12.3	30
336	May 2016 at a glance. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 456	12.3	
335	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 1771-8	3	23
334	Cardiac ANCA-associated vasculitis mimicking an acute coronary syndrome. <i>International Journal of Cardiology</i> , <b>2016</b> , 214, 200-1	3.2	1
333	Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9,	7.6	25
332	Carnosine: Potential aid for diabetes and cardiovascular disease. <i>Obesity</i> , <b>2016</b> , 24, 989	8	3
331	Chronic kidney disease and worsening renal function in acute heart failure: different phenotypes with similar prognostic impact?. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2016</b> , 5, 534-548	4.3	26
330	Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , <b>2016</b> , 4, 68-77	7.9	32
329	Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 404-11	3	38
328	Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. <i>International Journal of Cardiology</i> , <b>2016</b> , 204, 164-71	3.2	25
327	Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 1444-1455	15.1	142
326	Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. <i>Clinical Research in Cardiology</i> , <b>2016</b> , 105, 727-37	6.1	14
325	Sex Profile and Risk Assessment With Cardiopulmonary Exercise Testing in Heart Failure: Propensity Score Matching for Sex Selection Bias. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 754-9	3.8	14
324	Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow?. <i>Journal of Cardiac Failure</i> , <b>2016</b> , 22, 182-9	3.3	74
323	The metabolic exercise test data combined with Cardiac And Kidney Indexes (MECKI) score and prognosis in heart failure. A validation study. <i>International Journal of Cardiology</i> , <b>2016</b> , 203, 1067-72	3.2	25
322	Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS. <i>Journal of Cardiac Failure</i> , <b>2016</b> , 22, 815-22	3.3	21
321	MicroRNAs relate to early worsening of renal function in patients with acute heart failure. <i>International Journal of Cardiology</i> , <b>2016</b> , 203, 564-9	3.2	29
320	A combined clinical and biomarker approach to predict diuretic response in acute heart failure. <i>Clinical Research in Cardiology</i> , <b>2016</b> , 105, 145-53	6.1	25

319	Coronary Artery Disease and High Altitude: Unresolved Issues. <i>Research in Cardiovascular Medicine</i> , <b>2016</b> , 5, e32645	0.4	3
318	Nutritional Deficiency in Patients with Heart Failure. <i>Nutrients</i> , <b>2016</b> , 8,	6.7	48
317	Nutrition and Cardiovascular Disease: Finding the Perfect Recipe for Cardiovascular Health. <i>Nutrients</i> , <b>2016</b> , 8,	6.7	51
316	February 2016 at a glance. Focus issue on cardiac regeneration, medical treatment and cardiac devices. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 127	12.3	
315	European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 613-25	12.3	316
314	Signature of circulating microRNAs in patients with acute heart failure. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 414-23	12.3	125
313	The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 306-13	12.3	26
312	Optimizing clinical use of biomarkers in high-risk acute heart failure patients. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 269-80	12.3	54
311	March 2016 at a glance. Focus on right ventricular failure and acute heart failure. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 225-225	12.3	
310	Mitraclip therapy in patients with functional mitral regurgitation and missing leaflet coaptation: is it still an exclusion criterion?. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1278-1286	12.3	12
309	Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: data from the MECKI Score Research Group. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 545-53	12.3	44
308	Targeting N-Terminal Pro-Brain Natriuretic Peptide in Older Versus Younger Acute Decompensated Heart Failure Patients. <i>JACC: Heart Failure</i> , <b>2016</b> , 4, 736-45	7.9	9
307	Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 424-32	12.3	28
306	June 2016 at a glance: epidemiology, renal impairment, heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 587	12.3	1
305	Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 684-92	12.3	12
304	Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 830-9	12.3	51
303	April 2016 at a glance. Focus on cardiac remodeling, biomarkers and treatment. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 345-6	12.3	1
302	Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. <i>Lancet, The</i> , <b>2016</b> , 388, 2895-2903	40	158

301	December 2016 at a glance: cardiac metabolism, myocarditis, right ventricular function and prognostic markers. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1403-1404	12.3	
300	N-terminal pro-B-type natriuretic peptide-guided therapy in patients hospitalized for acute heart failure. <i>Journal of Cardiovascular Medicine</i> , <b>2016</b> , 17, 828-39	1.9	12
299	Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes: An Exploratory Analysis From the RELAX-AHF Trial. <i>JACC: Heart Failure</i> , <b>2016</b> , 4, 591-599	7.9	40
298	Management of acute heart failure in elderly patients. <i>Archives of Cardiovascular Diseases</i> , <b>2016</b> , 109, 422-30	2.7	17
297	Ascending Aortic Dimensions in Hypertensive Subjects: Reference Values for Two-Dimensional Echocardiography. <i>Journal of the American Society of Echocardiography</i> , <b>2016</b> , 29, 827-37	5.8	15
296	Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure - Post-hoc analysis of the PROTECT trial. <i>International Journal of Cardiology</i> , <b>2016</b> , 223, 967-975	3.2	6
295	September 2016 at a glance: pregnancy, hypertrophic cardiomyopathy, epidemiology, medical treatment. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1091-2	12.3	4
294	July 2016 at a glance: the critical role of co-morbidities. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 735	12.3	0
293	Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). <i>Circulation: Heart Failure</i> , <b>2016</b> , 9,	7.6	10
292	Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. <i>International Journal of Cardiology</i> , <b>2016</b> , 224, 231-239	3.2	42
291	Acute heart failure in the young: Clinical characteristics and biomarker profiles. <i>International Journal of Cardiology</i> , <b>2016</b> , 221, 1067-72	3.2	10
290	August 2016 at a glance: the new ESC guidelines, and pathophysiology, epidemiology and prognosis of heart failure. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 889-90	12.3	3
289	Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1153-61	12.3	59
288	Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper. <i>International Journal of Cardiology</i> , <b>2016</b> , 222, 303-312	3.2	78
287	Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9,	7.6	55
286	Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 641-9	12.3	20
285	Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 160-8	12.3	58
284	Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 290-7	12.3	33



283	A new format for the journal and a farewell. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 7	12.3	
282	Prognostic value of diastolic dysfunction in asymptomatic rheumatoid arthritis patients without cardiovascular risk factors. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 352	2.2	2
281	Echocardiographic evaluation of aortic atheromas in patients with aortic stenosis. <i>Journal of Ultrasound in Medicine</i> , <b>2015</b> , 34, 105-10	2.9	1
280	N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Measurements Until a 30% Reduction Is Attained During Acute Decompensated Heart Failure Admissions and Comparison With Discharge NT-proBNP Levels: Implications for In-Hospital Guidance of Treatment. <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, 930-4	3.3	12
279	April 2015 at a glance. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 347	12.3	
278	March 2015 at a glance. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 235-6	12.3	
277	May 2015 at a glance. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 465	12.3	
276	Reply: Mode of Death Prevention by Serelaxin. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 99	15.1	
275	Tako-tsubo cardiomyopathy in two sisters: a chance finding or familial predisposition?. <i>Clinical Research in Cardiology</i> , <b>2015</b> , 104, 614-6	6.1	3
274	Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations. <i>Heart Failure Reviews</i> , <b>2015</b> , 20, 393-400	5	3
273	Effectiveness of MitraClip therapy in patients with refractory heart failure. <i>Journal of Interventional Cardiology</i> , <b>2015</b> , 28, 61-8	1.8	14
272	Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 395-403	7.9	36
271	Role of different vascular approaches on transcatheter aortic valve implantation outcome: a single-center study. <i>Journal of Cardiovascular Medicine</i> , <b>2015</b> , 16, 279-85	1.9	15
270	Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. <i>American Heart Journal</i> , <b>2015</b> , 170, 290-7	4.9	41
269	Serum potassium decline during hospitalization for acute decompensated heart failure is a predictor of 6-month mortality, independent of N-terminal pro-B-type natriuretic peptide levels: An individual patient data analysis. <i>American Heart Journal</i> , <b>2015</b> , 170, 531-42.e1	4.9	16
268	Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 777-85	7.9	18
267	Competing Risk of Cardiac Status and Renal Function During Hospitalization for Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 751-61	7.9	31
266	Serelaxin a novel treatment for acute heart failure. <i>Expert Review of Clinical Pharmacology</i> , <b>2015</b> , 8, 549-53	3	

265	Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation. <i>European Journal of Preventive Cardiology</i> , <b>2015</b> , 22, 1046-55	3.9	24
264	Effects of oral administration of orodispersible levo-carnosine on quality of life and exercise performance in patients with chronic heart failure. <i>Nutrition</i> , <b>2015</b> , 31, 72-8	4.8	47
263	Ivabradine during cardiogenic shock: a clinical case and review of the literature. <i>Heart and Lung: Journal of Acute and Critical Care</i> , <b>2015</b> , 44, 57-8	2.6	10
262	Amino acids and derivatives, a new treatment of chronic heart failure?. <i>Heart Failure Reviews</i> , <b>2015</b> , 20, 39-51	5	20
261	Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 544-58	12.3	236
260	June 2015 at a glance. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 535	12.3	
259	Exercise Performance Is a Prognostic Indicator in Elderly Patients With Chronic Heart Failure--Application of Metabolic Exercise Cardiac Kidney Indexes Score. <i>Circulation Journal</i> , <b>2015</b> , 79, 2608-15	2.9	18
258	Renal function and peak exercise oxygen consumption in chronic heart failure with reduced left ventricular ejection fraction. <i>Circulation Journal</i> , <b>2015</b> , 79, 583-91	2.9	24
257	July 2015 at a glance. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 641	12.3	
256	Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1133-43	12.3	66
255	September 2015 at a glance. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 847-847	12.3	
254	November 2015 at a glance. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1085-1085	12.3	
253	Introduction. December 2015 at a glance. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1209	12.3	
252	Echocardiographic evaluation in subjects with $\alpha$ -Antitrypsin deficiency. <i>European Journal of Clinical Investigation</i> , <b>2015</b> , 45, 949-54	4.6	6
251	Endpoints in stem cell trials in ischemic heart failure. <i>Stem Cell Research and Therapy</i> , <b>2015</b> , 6, 159	8.3	12
250	Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1262-70	12.3	75
249	October 2015 at a glance. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 987-987	12.3	
248	August 2015 at a glance. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 749-749	12.3	

247	Prognostic value of RV isovolumic acceleration and tissue strain in moderate HFrEF. <i>European Journal of Clinical Investigation</i> , <b>2015</b> , 45, 1052-9	4.6	6
246	Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 697-706	12.3	21
245	In-hospital worsening heart failure. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1104-13	12.3	43
244	Agents with vasodilator properties in acute heart failure: how to design successful trials. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 652-64	12.3	24
243	Challenging the two concepts in determining the appropriate pre-discharge N-terminal pro-brain natriuretic peptide treatment target in acute decompensated heart failure patients: absolute or relative discharge levels?. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 936-44	12.3	17
242	The effect of aldosterone-antagonist therapy on aortic elastic properties in patients with nonischemic dilated cardiomyopathy. <i>Journal of Cardiovascular Medicine</i> , <b>2015</b> , 16, 597-602	1.9	18
241	Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine--short version. <i>European Heart Journal</i> , <b>2015</b> , 36, 1958-66	9.5	75
240	Characteristics and mid-term follow-up of a single-center population affected by Tako-Tsubo cardiomyopathy. <i>Journal of Cardiovascular Medicine</i> , <b>2015</b> , 16, 326-30	1.9	3
239	Prognostic role of atrial fibrillation in patients affected by chronic heart failure. Data from the MECKI score research group. <i>European Journal of Internal Medicine</i> , <b>2015</b> , 26, 515-20	3.9	14
238	Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. <i>Future Cardiology</i> , <b>2015</b> , 11, 585-95	1.3	16
237	Effects of spironolactone on ventricular-arterial coupling in patients with chronic systolic heart failure and mild symptoms. <i>Clinical Research in Cardiology</i> , <b>2015</b> , 104, 1078-87	6.1	15
236	Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 40-49	7.9	31
235	Acute heart failure in the elderly: differences in clinical characteristics, outcomes, and prognostic factors in the VERITAS Study. <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, 179-88	3.3	47
234	Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 109-18	12.3	35
233	Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 193-201	7.9	62
232	Quantitative analysis of right ventricular (RV) function with echocardiography in chronic heart failure with no or mild RV dysfunction: comparison with cardiac magnetic resonance imaging. <i>Journal of Ultrasound in Medicine</i> , <b>2015</b> , 34, 247-55	2.9	23
231	Risk assessment for a high-altitude alpinist with coronary artery disease. <i>Heart, Lung and Vessels</i> , <b>2015</b> , 7, 268-70		2
230	Acute decompensated heart failure update. <i>Current Cardiology Reviews</i> , <b>2015</b> , 11, 53-62	2.4	25

229	Diuretic response in acute heart failure: clinical characteristics and prognostic significance. <i>European Heart Journal</i> , <b>2014</b> , 35, 1284-93	9.5	205
228	Is there a role for ivabradine beyond its conventional use?. <i>Cardiovascular Therapeutics</i> , <b>2014</b> , 32, 189-92	3.3	9
227	Renal function trajectories and clinical outcomes in acute heart failure. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 59-67	7.6	47
226	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. <i>European Heart Journal</i> , <b>2014</b> , 35, 2797-815	9.5	231
225	Role of aliskiren on arterial stiffness and endothelial function in patients with primary hypertension. <i>Journal of Clinical Hypertension</i> , <b>2014</b> , 16, 202-6	2.3	20
224	A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLLaboration on Acute decompensated Heart Failure: ELAN-HF Score. <i>Heart</i> , <b>2014</b> , 100, 115-25	5.1	79
223	Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 1591-8	15.1	50
222	Elastic aortic properties in patients with X syndrome. <i>Heart Lung and Circulation</i> , <b>2014</b> , 23, 114-8	1.8	4
221	Body mass index and mortality in acutely decompensated heart failure across the world: a global obesity paradox. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 778-85	15.1	168
220	Effects of transcatheter aortic valve implantation on ascending aorta wall elastic properties: Tissue Doppler imaging and strain Doppler echocardiography study. <i>International Journal of Cardiology Heart &amp; Vessels</i> , <b>2014</b> , 4, 198-202		4
219	Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives. <i>International Journal of Cardiology Heart &amp; Vessels</i> , <b>2014</b> , 3, 6-14		9
218	In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry. <i>International Journal of Cardiology</i> , <b>2014</b> , 173, 163-9	3.2	76
217	Liver function, in-hospital, and post-discharge clinical outcome in patients with acute heart failure-results from the relaxin for the treatment of patients with acute heart failure study. <i>Journal of Cardiac Failure</i> , <b>2014</b> , 20, 407-13	3.3	31
216	International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 614-24	12.3	57
215	Treatment with inotropes and related prognosis in acute heart failure: contemporary data from the Italian Network on Heart Failure (IN-HF) Outcome registry. <i>Journal of Heart and Lung Transplantation</i> , <b>2014</b> , 33, 1056-65	5.8	21
214	Echocardiographic elastic properties of ascending aorta and their relationship with exercise capacity in patients with non-ischemic dilated cardiomyopathy. <i>International Journal of Cardiology Heart &amp; Vessels</i> , <b>2014</b> , 3, 78-81		1
213	Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. <i>Heart Failure Reviews</i> , <b>2014</b> , 19, 135-52	5	39
212	Effects of oral amino Acid supplements on functional capacity in patients with chronic heart failure. <i>Clinical Medicine Insights: Cardiology</i> , <b>2014</b> , 8, 39-44	3.2	34

211	Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function	7.6	97
210	Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 1362-71	12.3	22
209	Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. <i>European Heart Journal</i> , <b>2014</b> , 35, 1041-50	9.5	72
208	A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. <i>European Heart Journal</i> , <b>2014</b> , 35, 431-41	9.5	94
207	Reply: To PMID 24708382. <i>Journal of Clinical Hypertension</i> , <b>2014</b> , 16, 694	2.3	
206	Evaluation of ascending aorta wall in rheumatoid arthritis by tissue and strain Doppler imaging during anti-tumor necrosis factor- $\alpha$ therapy. <i>Clinical Cardiology</i> , <b>2014</b> , 37, 738-43	3.3	10
205	A case of a fistula between myxoma and a branch of right coronary artery. <i>Echocardiography</i> , <b>2014</b> , 31, E289-90	1.5	
204	Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 1230-40	12.3	95
203	Noninvasive assessment of endothelial function: the classic methods and the new peripheral arterial tonometry. <i>Journal of Investigative Medicine</i> , <b>2014</b> , 62, 856-64	2.9	11
202	Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms. <i>American Journal of the Medical Sciences</i> , <b>2014</b> , 347, 271-6	2.2	17
201	Transcatheter treatment of chronic mitral regurgitation with the MitraClip system: an Italian consensus statement. <i>Journal of Cardiovascular Medicine</i> , <b>2014</b> , 15, 173-88	1.9	9
200	High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. <i>Journal of Cardiac Failure</i> , <b>2014</b> , 20, 319-26	3.3	37
199	Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. <i>Heart Failure Reviews</i> , <b>2013</b> , 18, 107-22	5	39
198	Not time to RELAX in acute heart failure - Authors' reply. <i>Lancet, The</i> , <b>2013</b> , 381, 1813-4	4.0	1
197	Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. <i>European Heart Journal</i> , <b>2013</b> , 34, 3128-36	9.5	48
196	Prognostic value of indeterminable anaerobic threshold in heart failure. <i>Circulation: Heart Failure</i> , <b>2013</b> , 6, 977-87	7.6	39
195	Clinical features, and in-hospital and 1-year mortalities of patients with acute heart failure and severe renal dysfunction. Data from the Italian Registry IN-HF Outcome. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 3691-7	3.2	19
194	Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 679-89	12.3	26

193	Risk following hospitalization in stable chronic systolic heart failure. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 885-91	12.3	40
192	Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 61, 820-9	15.1	85
191	The potential role of nonpharmacologic electrophysiology-based interventions in improving outcomes in patients hospitalized for heart failure. <i>Heart Failure Clinics</i> , <b>2013</b> , 9, 331-43, vi-vii	3.3	
190	Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: a multiparametric approach to heart failure prognosis. <i>International Journal of Cardiology</i> , <b>2013</b> , 167, 2710-8	3.2	131
189	Severe heart failure prognosis evaluation for transplant selection in the era of beta-blockers: role of peak oxygen consumption. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 5078-81	3.2	21
188	The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 61, 1973-81	15.1	131
187	Anticoagulation in heart failure: current status and future direction. <i>Heart Failure Reviews</i> , <b>2013</b> , 18, 797-813	3.1	22
186	Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 2186-94	3.2	167
185	Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 61, 196-206	15.1	325
184	Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. <i>Lancet, The</i> , <b>2013</b> , 381, 29-39	40	693
183	Soluble guanylate cyclase: a potential therapeutic target for heart failure. <i>Heart Failure Reviews</i> , <b>2013</b> , 18, 123-34	5	92
182	Sex-specific acute heart failure phenotypes and outcomes from PROTECT. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 1374-81	12.3	38
181	Adrenergic receptor gene polymorphism and left ventricular reverse remodelling after cardiac resynchronization therapy: preliminary results. <i>Europace</i> , <b>2013</b> , 15, 1475-81	3.9	12
180	Is there a rationale for antiplatelet therapy in acute heart failure?. <i>Circulation: Heart Failure</i> , <b>2013</b> , 6, 869-76	7.6	4
179	Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates?: Findings from ASCEND-HF. <i>Circulation: Heart Failure</i> , <b>2013</b> , 6, 727-32	7.6	85
178	Multicenter prospective observational study on acute and chronic heart failure: one-year follow-up results of IN-HF (Italian Network on Heart Failure) outcome registry. <i>Circulation: Heart Failure</i> , <b>2013</b> , 6, 473-81	7.6	131
177	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 1173-84	12.3	388
176	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 1082-94	12.3	143

175	Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 551-9	12.3	54
174	Heart failure in elderly patients: distinctive features and unresolved issues. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 717-23	12.3	103
173	EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 808-17	12.3	462
172	Task force on: 'Early markers of atherosclerosis: influence of age and sex'. <i>Journal of Cardiovascular Medicine</i> , <b>2013</b> , 14, 757-66	1.9	63
171	Need for ongoing anti arrhythmic drugs after ablation of atrial fibrillation. Review. <i>Recent Patents on Cardiovascular Drug Discovery</i> , <b>2013</b> , 8, 204-15		2
170	Six-year prognosis of diabetic patients with coronary artery disease. <i>European Journal of Clinical Investigation</i> , <b>2012</b> , 42, 376-83	4.6	12
169	Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 1257-64	12.3	82
168	Acute heart failure patient profiles, management and in-hospital outcome: results of the Italian Registry on Heart Failure Outcome. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 1208-17	12.3	93
167	The role of the kidney in heart failure. <i>European Heart Journal</i> , <b>2012</b> , 33, 2135-42	9.5	159
166	Design of the RELAXin in acute heart failure study. <i>American Heart Journal</i> , <b>2012</b> , 163, 149-55.e1	4.9	53
165	Hyponatremia and long-term outcomes in chronic heart failure--an observational study from the Duke Databank for Cardiovascular Diseases. <i>Journal of Cardiac Failure</i> , <b>2012</b> , 18, 74-81	3.3	44
164	The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. <i>Drug Safety</i> , <b>2012</b> , 35, 233-44	5.1	35
163	Functional and hemodynamic cardiac determinants of exercise capacity in patients with systolic heart failure. <i>American Journal of Cardiology</i> , <b>2012</b> , 110, 1336-41	3	14
162	DO COUNTRIES OR HOSPITALS WITH LONGER STAYS HAVE LOWER READMISSION RATES? FINDINGS FROM THE ASCEND-HF TRIAL. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, E1029	15.1	3
161	Pioglitazone improves in vitro viability and function of endothelial progenitor cells from individuals with impaired glucose tolerance. <i>PLoS ONE</i> , <b>2012</b> , 7, e48283	3.7	32
160	Can we prevent or treat renal dysfunction in acute heart failure?. <i>Heart Failure Reviews</i> , <b>2012</b> , 17, 291-303		14
159	Can we prevent or treat renal dysfunction in chronic heart failure?. <i>Heart Failure Reviews</i> , <b>2012</b> , 17, 283-90		7
158	Renal dysfunction in acute heart failure: epidemiology, mechanisms and assessment. <i>Heart Failure Reviews</i> , <b>2012</b> , 17, 271-82	5	23

157	Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation. <i>Clinical Research in Cardiology</i> , <b>2012</b> , 101, 663-72	6.1	35
156	The European CRT Survey: 1 year (9-15 months) follow-up results. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 61-73	12.3	74
155	Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 219-25	12.3	123
154	The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 605-12	12.3	99
153	Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. <i>Circulation: Heart Failure</i> , <b>2012</b> , 5, 54-62	7.6	288
152	Elastic properties of the ascending aorta in patients with $\alpha$ -antitrypsin deficiency (Z homozygotes). <i>Heart</i> , <b>2012</b> , 98, 1354-8	5.1	16
151	Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofoylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents. <i>Drugs</i> , <b>2011</b> , 71, 515-25	15.1	109
150	Elastic properties of the ascending aorta in patients with rheumatoid arthritis. <i>International Journal of Cardiology</i> , <b>2011</b> , 150, 368-9	3.2	7
149	Antagonism of the Sympathetic Nervous System in Heart Failure <b>2011</b> , 674-693		3
148	Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure. <i>Journal of Cardiovascular Medicine</i> , <b>2011</b> , 12, 76-84	1.9	45
147	Old and new intravenous inotropic agents in the treatment of advanced heart failure. <i>Progress in Cardiovascular Diseases</i> , <b>2011</b> , 54, 97-106	8.5	18
146	Anaemia and heart failure. <i>Open Medicine (Poland)</i> , <b>2011</b> , 6, 11-25	2.2	
145	Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF. <i>Clinical Research in Cardiology</i> , <b>2011</b> , 100, 745-53	6.1	11
144	Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. <i>European Journal of Heart Failure</i> , <b>2011</b> , 13, 961-7	12.3	83
143	Clinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure, 12 May 2009. <i>European Journal of Heart Failure</i> , <b>2011</b> , 13, 1253-60	12.3	27
142	Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. <i>European Heart Journal</i> , <b>2011</b> , 32, 2563-72	9.5	99
141	Thromboembolism and antithrombotic therapy in patients with heart failure in sinus rhythm: current status and future directions. <i>Circulation: Heart Failure</i> , <b>2011</b> , 4, 361-8	7.6	25
140			



139	Neurohormonal activation in acute heart failure: results from VERITAS. <i>Cardiology</i> , <b>2011</b> , 119, 96-105	1.6	44
138	Can we improve the treatment of congestion in heart failure?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 1369-79	4	13
137	Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study. <i>Circulation: Heart Failure</i> , <b>2011</b> , 4, 724-32	7.6	73
136	Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. <i>European Heart Journal</i> , <b>2011</b> , 32, 1519-34	9.5	74
135	Chapter 49 Acute heart failure: epidemiology, classification, and pathophysiology <b>2011</b> ,		2
134	Measurement of the myocardial performance index in ambulatory patients with heart failure: correlation with other clinical and echocardiographic parameters and independent prognostic value. <i>Echocardiography</i> , <b>2010</b> , 27, 123-9	1.5	4
133	n-3 PUFAs and cardiovascular disease prevention. <i>Future Cardiology</i> , <b>2010</b> , 6, 343-50	1.3	26
132	Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 1130-9	12.3	73
131	Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function. <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 1238-46	12.3	13
130	EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 1076-84	12.3	258
129	Ventilatory efficiency and the selection of patients for heart transplantation. <i>Circulation: Heart Failure</i> , <b>2010</b> , 3, 378-86	7.6	39
128	Acute heart failure clinical drug development: from planning to proof of activity to phase III. <i>Cardiology</i> , <b>2010</b> , 116, 292-301	1.6	9
127	Low lymphocyte ratio as a novel prognostic factor in acute heart failure: results from the Pre-RELAX-AHF study. <i>Cardiology</i> , <b>2010</b> , 117, 190-6	1.6	13
126	Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 133-43	12.3	436
125	Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure--association with signs and symptoms, hospitalization duration, and 60-day outcomes. <i>Cardiology</i> , <b>2010</b> , 115, 29-36	1.6	41
124	Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release. <i>Drugs</i> , <b>2010</b> , 70, 41-56	12.1	43
123	Acute heart failure: multiple clinical profiles and mechanisms require tailored therapy. <i>International Journal of Cardiology</i> , <b>2010</b> , 144, 175-9	3.2	51
122	Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. <i>Journal of Cardiac Failure</i> , <b>2010</b> , 16, 25-35	3.3	72

121	The effects of adenosine A(1) receptor antagonism in patients with acute decompensated heart failure and worsening renal function: the REACH UP study. <i>Journal of Cardiac Failure</i> , <b>2010</b> , 16, 714-9	3.3	22
120	Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. <i>American Heart Journal</i> , <b>2010</b> , 159, 841-849.e1	4.9	172
119	Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 1419-28	59.2	407
118	Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study. <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 499-507	12.3	50
117	Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. <i>Circulation: Heart Failure</i> , <b>2010</b> , 3, 314-25	7.6	120
116	Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. <i>Clinical Research in Cardiology</i> , <b>2010</b> , 99, 75-82	6.1	14
115	Relaxin: review of biology and potential role in treating heart failure. <i>Current Heart Failure Reports</i> , <b>2010</b> , 7, 75-82	2.8	110
114	Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. <i>Cardiovascular Drugs and Therapy</i> , <b>2010</b> , 24, 49-60	3.9	54
113	Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. <i>American Journal of Cardiology</i> , <b>2010</b> , 106, 1292-6	3	49
112	Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2009</b> , 3, 11-4	4.9	8
111	Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. <i>European Heart Journal</i> , <b>2009</b> , 30, 3015-26	9.5	93
110	Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2009</b> , 11, 433-43	12.3	350
109	Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials. <i>European Journal of Heart Failure</i> , <b>2009</b> , 11, 256-63	12.3	9
108	The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy. <i>Cardiovascular Drugs and Therapy</i> , <b>2009</b> , 23, 5-15	3.9	47
107	Response to the Letter of Hester Den Ruijter and Ruben Coronel Regarding the Article "The Role of n-3 PUFAs in Preventing the Arrhythmic Risk in Patients with Idiopathic Dilated Cardiomyopathy" <i>Cardiovascular Drugs and Therapy</i> , <b>2009</b> , 23, 335-336	3.9	
106	Vasodilators in the treatment of acute heart failure: what we know, what we don't. <i>Heart Failure Reviews</i> , <b>2009</b> , 14, 299-307	5	45
105	Relaxin, a pleiotropic vasodilator for the treatment of heart failure. <i>Heart Failure Reviews</i> , <b>2009</b> , 14, 321-9		92
104	Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?. <i>Heart Failure Reviews</i> , <b>2009</b> , 14, 277-87	5	34

103	Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. <i>Heart Failure Reviews</i> , <b>2009</b> , 14, 243-53	5	74
102	Nuclear cardiology and heart failure. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2009</b> , 36, 2068-80	8.8	8
101	Vasodilators in Acute Heart Failure (AHF): Does Blood Pressure Matter? Results from Pre-Relax-AHF. <i>Journal of Cardiac Failure</i> , <b>2009</b> , 15, S74	3.3	2
100	Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). <i>American Heart Journal</i> , <b>2009</b> , 157, 219-28	4.9	27
99	Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. <i>American Heart Journal</i> , <b>2009</b> , 157, 957-70	4.9	43
98	Micronutrient deficiencies an unmet need in heart failure. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, 1660-73	15.1	102
97	Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. <i>Lancet, The</i> , <b>2009</b> , 373, 1429-39	4.0	334
96	Treatment of heart failure in the elderly: never say it's too late. <i>European Heart Journal</i> , <b>2009</b> , 30, 391-3	9.5	13
95	Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF). <i>Journal of Cardiac Failure</i> , <b>2008</b> , 14, 777-84	3.3	36
94	The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. <i>Journal of Cardiac Failure</i> , <b>2008</b> , 14, 631-40	3.3	146
93	Right ventricular thrombus and pulmonary thromboembolism/thrombosis in Behçet's disease: a case report. <i>Journal of the American Society of Echocardiography</i> , <b>2008</b> , 21, 1079	5.8	6
92	Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. <i>European Heart Journal</i> , <b>2008</b> , 29, 1644-52	9.5	192
91	Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. <i>European Journal of Heart Failure</i> , <b>2008</b> , 10, 188-95	12.3	285
90	Fluid overload in acute heart failure--re-distribution and other mechanisms beyond fluid accumulation. <i>European Journal of Heart Failure</i> , <b>2008</b> , 10, 165-9	12.3	219
89	CA 125 tumoral marker plasma levels relate to systolic and diastolic ventricular function and to the clinical status of patients with chronic heart failure. <i>Echocardiography</i> , <b>2008</b> , 25, 955-60	1.5	19
88	Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 49, 963-71	15.1	56
87	The safety of amiodarone in patients with heart failure. <i>Journal of Cardiac Failure</i> , <b>2007</b> , 13, 340-5	3.3	40
86	Anemia and Heart Failure: A Cause of Progression or Only a Consequence?. <i>Heart International</i> , <b>2007</b> , 3, 182618680700300	0.3	1

85	Long-term survival of patients with heart failure and ventricular conduction delay treated with cardiac resynchronization therapy. <i>American Journal of Cardiology</i> , <b>2007</b> , 99, 232-8	3	74
84	Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 684-94	12.3	265
83	Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 795-801	12.3	60
82	Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 1128-35	12.3	30
81	Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 901-9	12.3	71
80	The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 776-86	12.3	122
79	Treatment of advanced chronic heart failure with normal left ventricular ejection fraction. Response to the letter by Dr. Martinez-Selles. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 1224-1225	12.3	1
78	Beta-blocker therapy of heart failure: an update. <i>Expert Opinion on Pharmacotherapy</i> , <b>2007</b> , 8, 289-98	4	2
77	Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. <i>JAMA - Journal of the American Medical Association</i> , <b>2007</b> , 298, 2009-19	27.4	289
76	Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial. <i>American Heart Journal</i> , <b>2007</b> , 154, 861-9	4.9	23
75	Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). <i>Heart</i> , <b>2007</b> , 93, 968-73	5.1	110
74	Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. <i>European Heart Journal</i> , <b>2007</b> , 28, 230-68	9.5	1105
73	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , <b>2007</b> , 28, 88-136	9.5	889
72	Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results. <i>Therapeutics and Clinical Risk Management</i> , <b>2007</b> , 3, 569-78	2.9	5
71	The Prevention of Sudden Death: New Perspectives <b>2007</b> , 205-213		
70	Anemia and heart failure: a cause of progression or only a consequence?. <i>Heart International</i> , <b>2007</b> , 3, 1	0.3	
69	Prognostic value of cardiopulmonary exercise variables in chronic heart failure patients with or without beta-blocker therapy. <i>American Journal of Cardiology</i> , <b>2006</b> , 98, 500-3	3	26
68	ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death—executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Associat. <i>European Heart Journal</i> , <b>2006</b> , 27, 2099-140	9.5	360

67	The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. <i>European Heart Journal</i> , <b>2006</b> , 27, 1440-6	9.5	164
66	Role of beta1- and alpha2c-adrenergic receptor polymorphisms and their combination in heart failure: a case-control study. <i>European Journal of Heart Failure</i> , <b>2006</b> , 8, 131-5	12.3	26
65	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) developed in collaboration with the European Heart Rhythm Association and the Heart Failure Society of Europe. <i>Circulation</i> , <b>2006</b> , 114, e385-484	16.7	901
64	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation Executive Summary. <i>Circulation</i> , <b>2006</b> , 114, 700-752	16.7	237
63	ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop the 2006 Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) developed in collaboration with the European Heart Rhythm Association and the Heart Failure Society of Europe. <i>Circulation</i> , <b>2006</b> , 114, e385-484	3.9	392
62	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop the 2006 Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Failure Society of Europe. <i>Circulation</i> , <b>2006</b> , 114, e385-484	9.5	479
61	ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop the 2006 Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Failure Society of Europe. <i>Circulation</i> , <b>2006</b> , 114, e385-484	16.7	1653
60	ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop the 2006 Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) developed in collaboration with the European Heart Rhythm Association and the Heart Failure Society of Europe. <i>Circulation</i> , <b>2006</b> , 114, e385-484	15.1	972
59	A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET). <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 47, 1603-11	15.1	53
58	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death Executive Summary. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 48, 1064-1108	15.1	110
57	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop the 2006 Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Failure Society of Europe. <i>Circulation</i> , <b>2006</b> , 114, e385-484	15.1	865
56	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop the 2006 Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Failure Society of Europe. <i>Circulation</i> , <b>2006</b> , 114, e385-484	3.9	530
55	Optimal pharmacologic and non-pharmacologic management of cardiac transplant candidates: approaches to be considered prior to transplant evaluation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006. <i>Journal of Heart and Lung Transplantation</i> , <b>2006</b> , 25, 1003-23	5.8	44
54	Endothelial Damage Due to Air Pollution. <i>Heart International</i> , <b>2006</b> , 2, 182618680600200	0.3	
53	Managing heart failure in the very old. <i>Aging Health</i> , <b>2006</b> , 2, 253-275		
52	Usefulness of cardiac calcification on two-dimensional echocardiography for distinguishing ischaemic from nonischaemic dilated cardiomyopathy: a preliminary report. <i>Journal of Cardiovascular Medicine</i> , <b>2006</b> , 7, 182-7	1.9	5
51	Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. <i>European Heart Journal</i> , <b>2005</b> , 26, 1303-8	9.5	486
50	Symptoms in patients with heart failure are prognostic predictors: insights from COMET. <i>Journal of Cardiac Failure</i> , <b>2005</b> , 11, 288-92	3.3	145

49	Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. <i>European Heart Journal</i> , <b>2005</b> , 26, 2259-68	9.5	134
48	Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET. <i>American Heart Journal</i> , <b>2005</b> , 149, 370-6	4.9	61
47	Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). <i>American Heart Journal</i> , <b>2005</b> , 150, 46-53	4.9	58
46	Rationale and design of the enoximone clinical trials program. <i>Journal of Cardiac Failure</i> , <b>2005</b> , 11, 659-69	3	19
45	Pathophysiologic targets in the early phase of acute heart failure syndromes. <i>American Journal of Cardiology</i> , <b>2005</b> , 96, 11G-17G	3	197
44	Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial). <i>European Journal of Heart Failure</i> , <b>2005</b> , 7, 640-9	12.3	25
43	Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. <i>European Heart Journal</i> , <b>2005</b> , 26, 384-416	9.5	950
42	Current guidelines in the pharmacological management of chronic heart failure. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , <b>2004</b> , 5 Suppl 1, S11-6	3	2
41	Left internal thoracic artery-radial artery composite grafts as the technique of choice for myocardial revascularization in elderly patients: a prospective randomized evaluation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2004</b> , 127, 179-84	1.5	63
40	A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET). <i>Cardiovascular Drugs and Therapy</i> , <b>2004</b> , 18, 139-52	3.9	9
39	Beta-blockers in heart failure: are pharmacological differences clinically important?. <i>Heart Failure Reviews</i> , <b>2004</b> , 9, 123-30	5	40
38	Role of beta1- and beta2-adrenoceptor polymorphisms in heart failure: a case-control study. <i>European Heart Journal</i> , <b>2004</b> , 25, 1534-41	9.5	34
37	Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. <i>European Journal of Heart Failure</i> , <b>2003</b> , 5, 621-7	12.3	98
36	Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. <i>European Journal of Heart Failure</i> , <b>2003</b> , 5, 803-9	12.3	15
35	Prevention and management of chronic heart failure in patients at risk. <i>American Journal of Cardiology</i> , <b>2003</b> , 91, 10F-17F	3	17
34	Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. <i>Journal of the American College of Cardiology</i> , <b>2003</b> , 41, 1805-11	15.1	122
33	Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. <i>Lancet, The</i> , <b>2003</b> , 362, 7-13	40	1400
32	Off-pump coronary artery bypass surgery technique for total arterial myocardial revascularization: a prospective randomized study. <i>Annals of Thoracic Surgery</i> , <b>2003</b> , 76, 778-82; discussion 783	2.7	99

31	Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. <i>American Heart Journal</i> , <b>2003</b> , 145, 292-9	4.9	94
30	Fibroblast growth factor receptor-1 is essential for in vitro cardiomyocyte development. <i>Circulation Research</i> , <b>2003</b> , 93, 414-20	15.7	106
29	Is total arterial myocardial revascularization with composite grafts a safe and useful procedure in the elderly?. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2003</b> , 23, 657-64; discussion 664	3	18
28	Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. <i>European Journal of Heart Failure</i> , <b>2002</b> , 4, 321-9	12.3	61
27	Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 40, 1248-58	15.1	179
26	Beta-blockade in heart failure: selective versus nonselective agents. <i>American Journal of Cardiovascular Drugs</i> , <b>2001</b> , 1, 3-14	4	14
25	Selective or nonselective beta-adrenergic blockade in patients with congestive heart failure. <i>Current Cardiology Reports</i> , <b>2000</b> , 2, 252-7	4.2	1
24	Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. <i>Circulation</i> , <b>2000</b> , 102, 546-51	16.7	282
23	A rationale for the use of beta-blockers as standard treatment for heart failure. <i>American Heart Journal</i> , <b>2000</b> , 139, 511-21	4.9	53
22	PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. <i>Circulation</i> , <b>2000</b> , 102, 636-41	16.7	345
21	Beta Blockers in Heart Failure: Issues in Management of Individual Patients. <i>Heart Failure Reviews</i> , <b>1999</b> , 4, 65-78	5	2
20	Use of cardiopulmonary exercise testing with hemodynamic monitoring in the prognostic assessment of ambulatory patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , <b>1999</b> , 33, 943-50	15.1	100
19	Maximal and Submaximal Exercise Testing in Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , <b>1998</b> , 32, S36-S45	3.1	4
18	Maximal and submaximal exercise testing in heart failure. <i>Journal of Cardiovascular Pharmacology</i> , <b>1998</b> , 32 Suppl 1, S36-45	3.1	8
17	Long-term changes in left ventricular mass, chamber size and function after valve replacement in patients with severe aortic stenosis and depressed ejection fraction. <i>Cardiology</i> , <b>1997</b> , 88, 315-22	1.6	5
16	Pharmacological activity of the new calcium antagonist, lacidipine, on isolated preparations. <i>General Pharmacology</i> , <b>1996</b> , 27, 1255-9		2
15	Clinical efficacy of ibopamine in patients with chronic heart failure. <i>Clinical Cardiology</i> , <b>1995</b> , 18, 122-31	3.3	1
14	Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine. <i>Journal of Cardiovascular Pharmacology</i> , <b>1995</b> , 25, 732-40 <sup>3.1</sup>		6

13	Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. <i>Journal of the American College of Cardiology</i> , <b>1994</b> , 24, 1678-87	15.1	273
12	Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. <i>American Heart Journal</i> , <b>1994</b> , 128, 564-74	4.9	141
11	Pulmonary hypertension and systemic hypotension as limitations to exercise in chronic heart failure. <i>Journal of Cardiac Failure</i> , <b>1994</b> , 1, 27-33	3.3	7
10	Combined invasive and noninvasive study of left ventricular systolic and diastolic function following acute administration of cicloprolol to subjects with normal cardiac function. <i>Cardiovascular Drugs and Therapy</i> , <b>1992</b> , 6, 513-7	3.9	
9	Exercise hyperventilation chronic congestive heart failure, and its relation to functional capacity and hemodynamics. <i>American Journal of Cardiology</i> , <b>1992</b> , 70, 622-8	3	163
8	Effects of acute and chronic ibopamine administration on resting and exercise hemodynamics, plasma catecholamines and functional capacity of patients with chronic congestive heart failure. <i>American Journal of Cardiology</i> , <b>1992</b> , 70, 629-34	3	20
7	Improvement in exercise capacity after correction of anemia in patients with end-stage renal failure. <i>American Journal of Cardiology</i> , <b>1991</b> , 68, 1060-6	3	63
6	Assessment of peak oxygen consumption, lactate and ventilatory thresholds and correlation with resting and exercise hemodynamic data in chronic congestive heart failure. <i>American Journal of Cardiology</i> , <b>1990</b> , 65, 1127-33	3	77
5	Diagnosis of acute myocardial infarction by indium-111 antimyosin antibodies and correlation with the traditional techniques for the evaluation of extent and localization. <i>American Journal of Cardiology</i> , <b>1989</b> , 63, 7-13	3	47
4	Dopamine receptors in the stellate ganglion of the dog. <i>European Journal of Pharmacology</i> , <b>1989</b> , 164, 265-72	5.3	6
3	A randomized double-blind crossover study of nicardipine and nifedipine in patients with angina pectoris and concomitant essential hypertension. <i>Cardiovascular Drugs and Therapy</i> , <b>1988</b> , 1, 513-21	3.9	1
2	Diagnostic accuracy of rest-exercise first pass ventriculography with a fast single crystal gamma camera in detecting coronary artery disease. Study of a group of male subjects without previous myocardial infarction. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>1987</b> , 13, 213-20		2
1	Integrated Heart Failure Management in the Patient with Heart Failure Caused by Left Ventricular Systolic Dysfunction1-30		